CEO Says Compugen to Post Revenue from Proteomics in Q4 | GenomeWeb

NEW YORK, Nov 3 - Compugen expects to generate revenues from sales of its proteomics product in the fourth quarter as the company makes further strides into this sector, CEO Eli Mintz said Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.